156040-03-8 Usage
Description
Epi NorgalanthaMine, also known as Epigalanthamine (E588025), is a derivative of Galanthamine (G188500) that is metabolized in rats, dogs, and humans. It is isolated from the plant Crinum asiaticum var. japonicum and is characterized by its off-white foam appearance.
Uses
Used in Pharmaceutical Industry:
Epi NorgalanthaMine is used as a pharmaceutical compound for its potential therapeutic applications. As a metabolite of Galanthamine, it may exhibit similar pharmacological properties, which could be harnessed for the development of new drugs or therapies.
Used in Research and Development:
Epi NorgalanthaMine is used as a research compound for studying its chemical properties, metabolic pathways, and potential interactions with other compounds. This information can be valuable for understanding its role in the body and for developing new drugs based on its structure and activity.
Used in Drug Metabolism Studies:
Epi NorgalanthaMine is used as a model compound in drug metabolism studies to investigate how it is processed and eliminated from the body. This can help researchers understand the metabolic pathways involved and potentially identify new targets for drug development.
Used in Toxicology Studies:
Epi NorgalanthaMine can be used in toxicology studies to evaluate its safety and potential side effects. This information is crucial for determining the appropriate dosages and administration methods for any therapeutic applications that may be developed from this compound.
Check Digit Verification of cas no
The CAS Registry Mumber 156040-03-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,0,4 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 156040-03:
(8*1)+(7*5)+(6*6)+(5*0)+(4*4)+(3*0)+(2*0)+(1*3)=98
98 % 10 = 8
So 156040-03-8 is a valid CAS Registry Number.
156040-03-8Relevant articles and documents
Selective N-Demethylation of galanthamine to norgalanthamine via a non classical Polonovski reaction
Mary, Aude,Renko, Dolor Zafiarisoa,Guillou, Catherine,Thal, Claude
, p. 5151 - 5152 (1997)
The previously unknown N-demethylation of galanthamine 1 to norgalanthamine 3 was selectively accomplished by a non classical Polonovski reaction using iron salts. This transformation constitutes the first example of the application of the Polonovski reaction to an N-oxide of a seven membered cyclic amine. Norgalanthamine is a valuable intermediate in new Solanthamine derivatives synthesis.
Galantamine derivatives with indole moiety: Docking, design, synthesis and acetylcholinesterase inhibitory activity
Atanasova, Mariyana,Stavrakov, Georgi,Philipova, Irena,Zheleva, Dimitrina,Yordanov, Nikola,Doytchinova, Irini
, p. 5382 - 5389 (2015)
The inhibitors of acetylcholinesterase are the main therapy against Alzheimer's disease. Among them, galantamine is the best tolerated and the most prescribed drug. In the present study, 41 galantamine derivatives with known acetylcholinesterase inhibitor
Galantamine derivatives as acetylcholinesterase inhibitors: Docking, design, synthesis, and inhibitory activity
Doytchinova, Irini,Atanasova, Mariyana,Stavrakov, Georgi,Philipova, Irena,Zheleva-Dimitrova, Dimitrina
, p. 163 - 176 (2017/10/25)
Galantamine (GAL) is a well-known acetylcholinesterase (AChE) inhibitor, and it is widely used for treatment of Alzheimer’s disease. GAL fits well in the catalytic site of AChE, but it is too short to block the peripheral anionic site (PAS) of the enzyme,
